...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Open Journal of Internal Medicine >Gender-Related Survival in Different Stages of Lung Cancer—A Population Study over 20 Years
【24h】

Gender-Related Survival in Different Stages of Lung Cancer—A Population Study over 20 Years

机译：肺癌不同阶段中与性别相关的生存率-一项长达20年的人口研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Tumour stage is the most important prognostic factor in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The aim of this study was to evaluate if female gender was a prognostic factor in different tumour stages in relation to histology and given therapy. Methods: From 1989-2008, 1497 patients in eastern Scania, in southern Sweden with 202,000 inhabitants, were referred and prospectively registered. Tumour stage, performance status, lung cancer type and primary therapy were registered. Results: In NSCLC, female patients in stages 1 and 2 who were treated with surgery had a better 5-year survival rate (79.4%), compared to males (60.6%; p = 0.0004). Female patients in stage 3 with active therapy (surgery and/or radiotherapy and/or chemotherapy) had a better 5-year survival than males (20.6% vs. 10.5%, respectively, p = 0.0006). Female patients with adenocarcinoma were favourable in stages 1-3. In stage 4, there was no survival difference between females and males. In SCLC, females with limited disease (LD) and active therapy (chemotherapy ±?radiotherapy ± surgery) had a higher 5-year survival rate (28%) than males (5.6%); p = 0.001. Females with extensive disease (ED) and active therapy (chemotherapy ± radiotherapy) had a better 5-year survival (3.9%) compared to males (0.7%); p = 0.023. In multivariate analyses, patient performance status at diagnosis was also an independent prognostic factor in all tumour stages of lung cancer. Conclusions: This population-based study corroborates a female survival advantage in NSCLC stages 1-3, but not in metastatic stage 4, and this is also demonstrated for the adenocarcinoma subgroup. The study also confirms better prognosis in females with SCLC in both LD and ED. The study also demonstrates the importance of patient performance status as a prognostic factor in all stages of lung cancer.
机译：简介：肿瘤分期是非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）中最重要的预后因素。这项研究的目的是评估女性在组织学和给予治疗方面在不同肿瘤阶段是否是预后因素。方法：从1989年至2008年，瑞典南部斯堪尼亚的1497名患者被转诊并进行了前瞻性登记。记录肿瘤分期，表现状态，肺癌类型和主要治疗方法。结果：在NSCLC中，接受手术治疗的1期和2期女性患者的5年生存率（79.4％）高于男性（60.6％; p = 0.0004）。接受积极治疗（手术和/或放疗和/或化疗）的3期女性患者的5年生存率比男性高（分别为20.6％和10.5％，p = 0.0006）。女性腺癌患者在1-3期中表现良好。在第4阶段，雌雄之间没有生存差异。在SCLC中，疾病（LD）有限且积极治疗（化学疗法±放射疗法±手术）的女性的5年生存率（28％）高于男性（5.6％）。 p ＝ 0.001。患有广泛疾病（ED）和积极治疗（化学疗法±放射疗法）的女性比男性（0.7 ％）有更好的5年生存率（3.9 ％）; p ＝ 0.023。在多变量分析中，诊断时的患者表现状况也是肺癌所有肿瘤分期的独立预后因素。结论：这项基于人群的研究证实了NSCLC 1-3期而非转移4期的女性生存优势，这在腺癌亚组中也得到了证实。该研究还证实了在LD和ED中SCLC女性的预后更好。该研究还证明了患者表现状况作为肺癌所有阶段的预后因素的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号